厄洛替尼治疗晚期肺癌患者导致皮疹与疗效相关性分析

The Correlation Analysis between Skin Rash and the Efficacy of Erlotinib in Advanced Non-small Cell Lung Cancer Patients

目的观察厄洛替尼治疗老年晚期非小细胞肺癌(NSCLC)过程中出现皮疹的严重程度与疗效的关系。方法 2008年11月～2011年8月48例Ⅳ期非小细胞肺癌患者给予口服厄洛替尼150mg/d,至病情进展或出现不可耐受的不良反应停药,主要观察目标为评价皮疹的严重程度与疗效的关系,次要目标为总生存时间、无进展生存期。结果厄洛替尼组无疾病进展时间7.3个月(1～12个月),中位生存时间18.3个月(1～30个月),主要毒副作用是皮疹和腹泄。结论皮疹的严重程度与疗效呈正相关,皮疹可作为预测和评价厄洛替尼治疗晚期非小细胞肺癌疗效的指标。

Objective To explore the relation of skin rash to the efficacy of Erlotinib in patients with advanced non-small cell lung cancer. Methods Retrospective analysis 48 cases IV period non-small cell lung cancer patients from November 2008 to August 2011, and gived oral Erlotinib 150mg/d, to progress or appear to do not tolerate adverse reaction of withdrawal.The main target for evaluation rash observation severity and curative effect of the relationship, the secondary objective for overall survival time, progression free survival.Results Erlotinib treatment group without progression of disease time 7.3months （ 1-12months ）, the median survival time 18.3 months （ 1-30 months ） .The main side effects was rash and abdomen dampened.Conclusion The severity of the rash and the curative effect are positively correlated.Rash＇can serve as urmson for predicting and evaluating the efficacy the treatment of advanced non-small cell lung cancer effective index.